Freeze-dried Live Attenuated Hepatitis A Vaccine >6.5LgCCID50

Freeze-dried Live Attenuated Hepatitis A Vaccine >6.5LgCCID50 is a live attenuated viral vaccine used to provide active immunization against infection caused by hepatitis A virus (HAV). The vaccine contains a weakened H2 strain of HAV produced in human diploid cell culture and formulated as a freeze-dried preparation with an infectious titre greater than 6.5 Lg CCID50 per dose. Unlike inactivated hepatitis A vaccines, it contains live but attenuated virus that stimulates the immune system to develop protective antibodies and cellular immune responses without producing typical hepatitis A disease in healthy vaccine recipients. The vaccine is reconstituted before administration and is given by subcutaneous injection. Current Indian product information indicates its use in children and adults from 1 year of age, with a single 0.5 mL dose generally providing adequate immunoprotection. Freeze-drying improves stability compared with earlier liquid formulations and permits refrigerated storage. The vaccine is clinically important for prevention of hepatitis A, a contagious liver infection commonly transmitted through contaminated food, water, or close personal contact. Because it is a live attenuated vaccine, careful assessment of immune status, acute illness, allergy history, and other vaccination precautions is important before administration.

Live attenuated hepatitis A vaccines were developed using attenuated HAV strains adapted through serial passage in cell culture. The H2 strain used in this type of vaccine was developed for vaccine production and has been used in China since the early development of live attenuated hepatitis A vaccination. Chinese live attenuated hepatitis A vaccines were initially licensed in liquid formulations in the 1990s, with freeze-dried formulations subsequently introduced to improve stability and extend shelf life. The freeze-dried H2 vaccine has been used in China and has also been evaluated and supplied in other countries. Indian regulatory records document permission for freeze-dried live attenuated hepatitis A vaccine products, including the current formulation marketed in India. The Indian product information for BIOVAC-A identifies permission number IMP/BIO/21/000090 dated 25 October 2021, with a product revision in July 2024. The Central Drugs Standard Control Organization has also listed freeze-dried live attenuated hepatitis A vaccines among biological products in India. Clinical development has included studies in healthy children and adults evaluating immunogenicity, safety, and persistence of antibody responses after a single subcutaneous dose. This vaccine class has not been approved by the FDA or EMA as a routine hepatitis A vaccine, and regulatory status varies by country.

Freeze-dried Live Attenuated Hepatitis A Vaccine >6.5LgCCID50 is indicated for active immunization against hepatitis A virus infection. Current Indian product information specifies use in adults and children above 1 year of age. It is intended for primary prevention of hepatitis A rather than treatment of an established HAV infection. A single dose is used according to the current Indian product information, and a booster dose is generally not required for this live attenuated formulation. The vaccine may be considered for individuals requiring protection against hepatitis A, including those living in or travelling to areas where hepatitis A is prevalent, subject to applicable national immunization recommendations and individual clinical assessment. It should be distinguished from inactivated hepatitis A vaccines, which have different formulations, routes, schedules, and regulatory indications.

The vaccine is supplied as a freeze-dried preparation that must be reconstituted with the supplied sterile water for injection before administration. For adults and children above 1 year of age, the current Indian product information specifies a single 0.5 mL dose administered subcutaneously over the deltoid region of the upper arm. The vial should be gently shaken after addition of the diluent until the powder is completely dissolved, and the reconstituted product should be inspected for abnormal appearance or particulate matter before injection. The vaccine should be stored and transported at 2°C to 8°C, protected from light, and should not be frozen. After opening or reconstitution, the product should be used within the period specified in the product information, generally within one hour. A booster dose is usually not required according to the current Indian product information. Vaccination should be administered by an appropriately trained healthcare professional, with observation and appropriate management capability for rare immediate allergic reactions.

Common side effects are generally mild and temporary. Reported reactions may include pain, tenderness, redness or swelling at the injection site, headache, fatigue, loss of appetite, nausea, vomiting, abdominal discomfort, fever, irritability, muscle discomfort, or rash. Some recipients may experience short-lived systemic symptoms as the immune response develops. Clinical studies of H2 live attenuated hepatitis A vaccine in Indian children reported generally good tolerability following vaccination, with local and systemic reactions monitored after administration. The frequency and severity of reactions can vary according to age, health status, and individual response to vaccination. Most expected reactions resolve without specific treatment, but persistent, severe, or unusual symptoms should be assessed by a healthcare professional.

Serious adverse events are uncommon, but live attenuated vaccines require particular attention to contraindications and immune status. Severe hypersensitivity or anaphylactic reactions can occur in individuals who are allergic to the vaccine or its components and require immediate medical management. The vaccine should not be administered to individuals with known hypersensitivity to its ingredients, including relevant excipients or residual production components. Live attenuated hepatitis A vaccines are generally unsuitable for individuals with significant immunodeficiency because vaccine virus replication may pose a risk in severely immunocompromised persons. Vaccination should also be deferred during acute febrile illness or significant acute infection according to the product information. Neurological events such as convulsion have been reported but are uncommon. Because this is a live vaccine, pregnancy and immunosuppressive conditions require careful medical assessment before vaccination. Appropriate observation after administration should be available to manage any immediate serious allergic reaction.

Before vaccination, healthcare professionals should review previous vaccine reactions, known allergies, current illness, immune status, pregnancy status where relevant, and use of immunosuppressive medicines. Particular caution is required in individuals with congenital or acquired immunodeficiency and those receiving significant immunosuppressive therapy, because immune responses may be reduced and administration of live vaccines may present additional safety concerns. Vaccination should generally be postponed during significant acute illness or fever until recovery. The vaccine should be maintained within the recommended cold chain at 2°C to 8°C and protected from light; freezing can damage vaccine viability. Classic drug interactions are limited, but immunosuppressive medicines may reduce the immune response and can affect the suitability of a live attenuated vaccine. Other live vaccines or immunomodulatory treatments should be considered in the overall vaccination plan. Pregnancy and breastfeeding decisions should be made by a qualified healthcare professional after weighing potential benefits and risks.

Prescribers should confirm that the patient is at least 1 year of age, verify the indication, review allergy and immune status, and assess for acute illness before vaccination. The product should remain within the cold chain during storage and transport, and the vial and diluent should be checked before reconstitution. Pharmacists and vaccinators should verify the correct diluent, dose, route, and administration technique and ensure that the vaccine is used within the specified period after reconstitution. The reconstituted vaccine should be visually inspected before administration and should not be used if there is unexpected discoloration or particulate matter. Patients or caregivers should be counselled about expected mild local or systemic reactions and advised to seek immediate medical attention for breathing difficulty, facial swelling, generalized allergic symptoms, seizure, or other serious reactions. Documentation of vaccine administration and post-vaccination observation should follow local immunization procedures.